Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2001

View Archived Issues

Liposomal FGF-2 vaccine shows antiangiogenic efficacy

Venlafaxine compared to SSRIs in major depressive disorder

Abbott and NaPro BioTherapeutics file ANDA for paclitaxel

Prous Science announces publication of "Rational Approaches to Drug Design"

Adenosine A1 antagonist BG-9719 has beneficial effects in CHF

Hemodynamic, neurohumoral and other effects of long-term darusentan in CHF patients

Rosuvastatin shows good clinical results, as reported at ACC Scientific Session

Ranolazine proves beneficial in CHF patients with chronic angina; improves LV mechanical efficiency

Two new antiglaucoma drugs approved by FDA

Vernalis to clinically evaluate VML-670 for sexual dysfunction

New genomics-proteomics alliance announced by European firms

Neurogen and Pfizer advance GABA modulators for various indications

AAAAI news: steroidal antiinflammatory IPL-576092 has a profile distinct from glucocorticoids

Pharmacokinetics/pharmacodynamics of ezetimibe plus atorvastatin assessed

ICN's ribavirin granted orphan drug designation for treatment of hemorrhagic fever in E.U.

Preliminary clinical efficacy, safety and PK results for IDEC-152 presented at AAAAI meeting

Eplerenone improves endothelial function in rabbit model of atherosclerosis

Antisense oligonucleotides designed at Isis to modulate Akt-3

Novel antisense compounds as antiasthmatic, antiarthritic agents

Chemokine receptor antagonists and their use described by SB (now GSK)

Improved calanolide-related compounds identified in India as potential agents for HIV

Banyu discloses muscarinic M3 receptor antagonists particularly useful in asthma Rx

Heptapeptide LHRH antagonists in the Abbott pipeline

Aventis prepares new streptogramin B derivatives

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 2, 2025.
Researchers arm CAR T cells to fight solid tumors
BioWorld Science
Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...
Bioversys, Shionogi in CHF529M lung infection collaboration
BioWorld Science
Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on...
Medtronic receives CE mark for its Vitalflow ECMO system
BioWorld MedTech
Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...